➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
AstraZeneca
Dow
McKinsey

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Biologic Drugs With Dosage Form: INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Details for Dosage Type: INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER

Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial Aegis Therapeutics LLC (San Diego, CA) 2026-06-23 RX Orphan search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial Atopix Therapeutics Limited (Abingdon, Oxon, GB) 2031-03-07 RX Orphan search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial Aegis Therapeutics, LLC (San Diego, CA) 2026-06-23 RX Orphan search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial Array BioPharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) 2027-07-05 RX Orphan search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial City of Hope (Duarte, CA) 2030-10-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Medtronic
Harvard Business School
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group